Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 10 results.
User Information
Export Records
  1. 1.   Role of GADD34 in modulation of cisplatin cytotoxicity
  2. Fishel, M. L.; Rabik, C. A.; Bleibel, W. K.; Li, X. M.; Moschel, R. C.; Dolan, M. E.
  3. Biochemical Pharmacology. 2006, JAN 12; 71(3): 239-247.
  1. 2.   Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy
  2. Sayers, T. J.; Murphy, W. J.
  3. Cancer Immunology Immunotherapy. 2006, JAN; 55(1): 76-84.
  1. 3.   Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by zebularine on L1210 leukemia
  2. Lemaire, M.; Momparler, L. F.; Bernstein, M. L.; Marquez, V. E.; Momparler, R. L.
  3. Anti-Cancer Drugs. 2005, MAR; 16(3): 301-308.
  1. 4.   Tumour stem cells and drug resistance
  2. Dean, M.; Fojo, T.; Bates, S.
  3. Nature Reviews Cancer. 2005 5(4): 275-284.
  1. 5.   Induction of stem cell factor/c-Kit/Slug signal transduction in multidrug-resistant malignant mesothelioma cells
  2. Catalano, A.; Rodilossi, S.; Rippo, M. R.; Caprari, P.; Procopio, A.
  3. Journal of Biological Chemistry. 2004, NOV 5; 279(45): 46706-46714.
  1. 6.   The experimental antitumor agents Phortress and Doxorubicin are equiactive against human-derived breast carcinoma xenograft models
  2. Fichtner, I.; Monks, A.; Hose, C.; Stevens, M. F. G.; Bradshaw, T. D.
  3. Breast Cancer Research and Treatment. 2004, SEP; 87(1): 97-107.
  1. 7.   Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XLAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database
  2. Nikolovska-Coleska, Z.; Xu, L.; Hu, Z. J.; Tomita, Y.; Li, P.; Roller, P. P.; Wang, R. X.; Fang, X. L.; Guo, R. B.; Zhang, M. C.; Lippman, M. E.; Yang, D. J.; Wang, S. M.
  3. Journal of Medicinal Chemistry. 2004 47(10): 2430-2440.
  1. 8.   Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation
  2. Liu, J.; Li, C. X.; Qu, W.; Leslie, E.; Bonifant, C. L.; Buzard, G. S.; Saavedra, J. E.; Keefer, L. K.; Waalkes, M. P.
  3. Molecular Cancer Therapeutics. 2004 3(6): 709-714.
  1. 9.   Regulating the p53 system through ubiquitination
  2. Yang, Y. L.; Li, C. C. H.; Weissman, A. M.
  3. Oncogene. 2004 23(11): 2096-2106.
  1. 10.   Characterization of the P53 Tumor Suppressor Pathway in Cell Lines of the National Cancer Institute Anticancer Drug Screen and Correlations With the Growth-Inhibitory Potency of 123 Anticancer Agents
  2. Oconnor, P. M.; Jackman, J.; Bae, I.; Myers, T. G.; Fan, S. J.; Mutoh, M.; Scudiero, D. A.; Monks, A.; Sausville, E. A.; Weinstein, J. N.; Friend, S.; Fornace, A. J.; Kohn, K. W.
  3. Cancer Research. 1997 57(19): 4285-4300.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel